文献速递主动脉疾病内脏/肾动脉与血管畸形

基因确诊血管型埃勒斯-当洛斯综合征的主动脉及动脉病变多机构经验

A multi-institutional experience in the aortic and arterial pathology in individuals with genetically confirmed vascular Ehlers-Danlos syndrome.
PubMed 文献 · J Vasc Surg · 2019-05-21

该多机构回顾性横断面研究纳入86例基因确诊血管型埃勒斯-当洛斯综合征(vEDS)患者,其中53例(61.6%)共诊断139处主动脉/动脉病变,最常见为肠系膜动脉(31.7%),37.4%以急症表现,多数行药物治疗,栓塞和支架耐受良好,开放腹主动脉瘤修复在部分患者中结果良好。

要点

  • vEDS患者主动脉/动脉病变常见,肠系膜动脉最常受累,急症表现比例较高。
  • 多数动脉病变可药物治疗,需干预时栓塞和支架耐受良好。
  • 开放腹主动脉瘤修复在vEDS患者中耐受良好,不应成为手术禁忌。

核心结论

  • 多数vEDS动脉表现采用药物治疗;需干预时栓塞和较少用的支架耐受良好;开放腹主动脉瘤修复耐受性与非vEDS患者相当,vEDS不应成为手术禁忌。

研究设计与样本

  • 多机构参与的血管低频率疾病联盟横断面回顾性研究,2000至2015年纳入86例基因确诊COL3A1致病性变异个体。

主要发现

  • 53例(61.6%)诊断139处主动脉/动脉病变,37.4%以急症表现。
  • 最常受累动脉为肠系膜动脉(31.7%),其次为脑血管(16.5%)、髂动脉(16.5%)和肾动脉(12.2%)。
  • 主要管理为药物治疗;干预以中等动脉栓塞(13.4%)为主,支架置入(2.5%)较少。
  • 17例(32%)有主动脉病变,其中4例成功行腹主动脉瘤修复且随访结果优良。
  • 12例死亡(22.6%),中位年龄36岁(IQR 28-51岁)。

关键数值与推荐

  • 基因确诊COL3A1致病性变异者86例,男47.7%,白人86%,中位年龄41岁(IQR 31.0-49.5岁),错义变异65.1%。
  • 有主动脉/动脉病变者53例,男50.9%,白人88.5%,中位年龄33岁(IQR 25.0-42.3岁)。
  • 主动脉病变者17例,男58.8%,白人94.1%,中位年龄38.5岁(IQR 30.8-44.7岁)。

临床怎么用

  • vEDS患者主动脉/动脉病变多可先行药物治疗。
  • 需干预增大动脉瘤或破裂时,栓塞和支架置入耐受良好。
  • 腹主动脉瘤开放修复在vEDS患者中耐受良好,不应视为禁忌。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vascular Ehlers-Danlos syndrome (vEDS) is a rare connective tissue disorder owing to pathogenic variants in COL3A1 that lead to impaired type III collagen production. We aim to describe the contemporary multi-institutional experience of aortic and arterial pathology in individuals with vEDS, to evaluate disease patterns and refine management recommendations. METHODS: This cross-sectional, retrospective study of individuals with genetically confirmed vEDS was conducted between 2000 and 2015 at multiple institutions participating in the Vascular Low Frequency Disease Consortium. Aortic and arterial events including aneurysms, pseudoaneurysms, dissections, fistulae, or ruptures were studied. Demographics, COL3A1 variants, management, and outcomes data were collected and analyzed. Individuals with and without arterial events were compared. RESULTS: Eleven institutions identified 86 individuals with pathogenic variants in COL3A1 (47.7% male, 86% Caucasian; median age, 41 years; interquartile range [IQR], 31.0-49.5 years; 65.1% missense COL3A1 variants). The median follow-up from the time of vEDS diagnosis was 7.5 years (IQR, 3.5-12.0 years). A total of 139 aortic/arterial pathologies were diagnosed in 53 individuals (61.6%; 50.9% male; 88.5% Caucasian; median age, 33 years; IQR, 25.0-42.3 years). The aortic/arterial events presented as an emergency in 52 cases (37.4%). The most commonly affected arteries were the mesenteric arteries (31.7%), followed by cerebrovascular (16.5%), iliac (16.5%), and renal arteries (12.2%). The most common management was medical management. When undertaken, the predominant endovascular interventions were arterial embolization of medium sized arteries (13.4%), followed by stenting (2.5%). Aortic pathology was noted in 17 individuals (32%; 58.8% male; 94.1% Caucasian; median age, 38.5 years; IQR, 30.8-44.7 years). Most notably, four individuals underwent successful abdominal aortic aneurysm repair with excellent results on follow-up. Individuals with missense mutations, in which glycine was substituted with a large amino acid, had an earlier onset of aortic/arterial pathology (median age, 30 years; IQR, 23.5-37 years) compared with the other pathogenic COL3A1 variants (median age, 36 years; IQR, 29.5-44.8 years; P = .065). There were 12 deaths (22.6%) at a median age of 36 years (IQR, 28-51 years). CONCLUSIONS: Most of the vEDS arterial manifestations were managed medically in this cohort. When intervention is required for an enlarging aneurysm or rupture, embolization, and less frequently stenting, seem to be well-tolerated. Open repair of abdominal aortic aneurysm seems to be as well-tolerated as in those without vEDS; vEDS should not be a deterrent to offering an operation. Future work to elucidate the role of surgical interventions and refine management recommendations in the context of patient centered outcomes is warranted.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shalhub S, Byers PH, Hicks KL, et al. A multi-institutional experience in the aortic and arterial pathology in individuals with genetically confirmed vascular Ehlers-Danlos syndrome. J Vasc Surg. 2019. PMID: 31126764. doi:10.1016/j.jvs.2019.01.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。